Related Experiment Videos
Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity?
Laboratory Investigation; a Journal of Technical Methods and Pathology
|September 1, 1987
Summary
This study found that medullary thyroid carcinomas (MCT) producing thyroglobulin, alongside calcitonin, represent a distinct tumor variant. Thyroglobulin-positive MCT may indicate a better patient prognosis compared to thyroglobulin-negative cases.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Medullary thyroid carcinoma (MCT) is a neuroendocrine tumor of the thyroid.
- MCTs typically produce calcitonin, but co-expression of other hormones like thyroglobulin is rare.
Purpose of the Study:
- To investigate the histological and immunohistochemical characteristics of MCTs expressing both thyroglobulin and calcitonin.
- To explore the potential origin and clinical implications of thyroglobulin immunoreactivity in MCTs.
Main Methods:
- Light microscopy and immunohistochemistry were employed on fourteen medullary thyroid carcinoma (MCT) samples.
- Double immunostaining was utilized to assess the co-localization of thyroglobulin, calcitonin, and calcitonin gene-related peptide within tumor cells.
Main Results:
- Thyroglobulin immunoreactivity was observed in neoplastic follicles and solid foci, including in lymph node metastases.
- Co-localization of thyroglobulin and calcitonin was detected in the same neoplastic cells in eight cases.
- Thyroglobulin also co-localized with calcitonin gene-related peptide in three cases, including one with metastases.
Conclusions:
- Thyroglobulin-positive MCT is likely an unusual variant of the multihormone-producing MCT.
- These findings support the hypothesis of a common stem cell origin for these tumors.
- Thyroglobulin-positive MCT may be associated with a more favorable prognosis than thyroglobulin-negative MCT.